Figure 2.

Kaplan–Meier plots of progression-free survival (PFS) and overall survival (OS) according to KRAS, BRAF, NRAS, and PIK3CA gene status. Figure  2 A. PFS: Median PFS values were 6.1 months [95% confidence interval (CI): 3.1–9.2], 2.7 months (1.2–4.2), and 1.6 months (1.5–1.7) among patients with all wild-type tumors (N = 49, blue line), KRAS codon 12 or 13 mutant tumors (N = 21, green line), and KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutant tumors (N = 12, gray-line), respectively. Differences in PFS values between patients with all wild-type tumors and those with KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutant tumors were statistically significant (hazard ratio, 0.22; 95% CI, 0.11–0.44; P < 0.0001). Figure  2 B. OS: Median OS values were 13.8 months [95% confidence interval (CI): 9.2–18.4], 8.2 months (5.7–10.7), and 6.3 months (1.3–11.3) among patients with all wild-type tumors (N = 49, blue line), with KRAS codon 12 or 13 mutant tumors (N = 21, green line), and with KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutations (N = 12, gray-line), respectively. Differences in OS values between patients with all wild-type tumors and those with KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutant tumors were statistically significant (hazard ratio, 0.30; 95% CI, 0.15–0.61; P < 0.0001).

Bando et al. BMC Cancer 2013 13:405   doi:10.1186/1471-2407-13-405
Download authors' original image